TY - JOUR
T1 - Patients’ perspectives on antimicrobial resistance in chronic respiratory disease
T2 - an AMR-Lung/European Lung Foundation global patient survey
AU - Papadopoulou, Efthymia
AU - Sykes, Dominic L.
AU - Goeminne, Pieter
AU - Machado, Ana
AU - Marghlani, Dareen
AU - McNeil, Lisa
AU - Norwell, Joyce
AU - Paixão, Cátia
AU - Shoemark, Amelia
AU - Boyd, Jeanette
AU - Ekkelenkamp, Miquel
AU - Thee, Stephanie
AU - Shah, Anand
N1 - Copyright:
© The authors 2025.
PY - 2025/11
Y1 - 2025/11
N2 - Background Antimicrobial resistance (AMR) represents a significant global health threat, particularly for people with chronic respiratory diseases. However, their experiences, knowledge, priorities and concerns have not been comprehensively assessed. This study aimed to gauge patients’ perspectives of AMR burden in chronic respiratory disease. Methods An anonymous web-based patient survey was developed by the AMR-Lung European Respiratory Society Clinical Research Collaboration and members of the European Lung Foundation patient advisory groups, consisting of 39 questions, translated into 20 languages and held online over a 2-month period. Multivariable logistic regression analyses were used to explore disease-specific burden and factors potentially affecting AMR across different healthcare settings. Results Among 2012 respondents from 57 countries on all six continents, 30.7% recalled having an AMR-associated infection, while 12.6% perceived their last antimicrobial course as ineffective. 30.5% received long-term prophylactic antimicrobials, with 44.6% of them recalling an AMR-associated infection. 17.6% reported antimicrobial use without medical prescription, while 9.5% perceived prescriptions as delayed. Respondents recognised mostly their healthcare professionals as an information source regarding AMR, but 27% were unaware of AMR prior to the survey. Patients from high-income countries were more likely to be knowledgeable about AMR, to avoid using antimicrobials without prescription and to perceive them as ineffective. Respondents overwhelmingly viewed AMR as a personal (76.4%) and global (79.6%) threat. Conclusions This global large-scale survey ascertains for the first time the high AMR burden from the perspective of people with chronic respiratory diseases, accentuating the need to promote AMR awareness, judicious antimicrobial use and accessibility to quality healthcare.
AB - Background Antimicrobial resistance (AMR) represents a significant global health threat, particularly for people with chronic respiratory diseases. However, their experiences, knowledge, priorities and concerns have not been comprehensively assessed. This study aimed to gauge patients’ perspectives of AMR burden in chronic respiratory disease. Methods An anonymous web-based patient survey was developed by the AMR-Lung European Respiratory Society Clinical Research Collaboration and members of the European Lung Foundation patient advisory groups, consisting of 39 questions, translated into 20 languages and held online over a 2-month period. Multivariable logistic regression analyses were used to explore disease-specific burden and factors potentially affecting AMR across different healthcare settings. Results Among 2012 respondents from 57 countries on all six continents, 30.7% recalled having an AMR-associated infection, while 12.6% perceived their last antimicrobial course as ineffective. 30.5% received long-term prophylactic antimicrobials, with 44.6% of them recalling an AMR-associated infection. 17.6% reported antimicrobial use without medical prescription, while 9.5% perceived prescriptions as delayed. Respondents recognised mostly their healthcare professionals as an information source regarding AMR, but 27% were unaware of AMR prior to the survey. Patients from high-income countries were more likely to be knowledgeable about AMR, to avoid using antimicrobials without prescription and to perceive them as ineffective. Respondents overwhelmingly viewed AMR as a personal (76.4%) and global (79.6%) threat. Conclusions This global large-scale survey ascertains for the first time the high AMR burden from the perspective of people with chronic respiratory diseases, accentuating the need to promote AMR awareness, judicious antimicrobial use and accessibility to quality healthcare.
UR - https://www.scopus.com/pages/publications/105026373881
U2 - 10.1183/23120541.00271-2025
DO - 10.1183/23120541.00271-2025
M3 - Article
C2 - 41367673
AN - SCOPUS:105026373881
SN - 2312-0541
VL - 11
JO - ERJ Open Research
JF - ERJ Open Research
IS - 6
M1 - 00271-2025
ER -
